Cargando…

Longitudinal Plasma Measures of Trimethylamine N‐Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community‐Based Older Adults

BACKGROUND: Trimethylamine N‐oxide (TMAO) is a gut microbiota‐dependent metabolite of dietary choline, L‐carnitine, and phosphatidylcholine‐rich foods. On the basis of experimental studies and patients with prevalent disease, elevated plasma TMAO may increase risk of atherosclerotic cardiovascular d...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yujin, Nemet, Ina, Wang, Zeneng, Lai, Heidi T. M., de Oliveira Otto, Marcia C., Lemaitre, Rozenn N., Fretts, Amanda M., Sotoodehnia, Nona, Budoff, Matthew, DiDonato, Joseph A., McKnight, Barbara, Tang, W. H. Wilson, Psaty, Bruce M., Siscovick, David S., Hazen, Stanley L., Mozaffarian, Dariush
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649305/
https://www.ncbi.nlm.nih.gov/pubmed/34398665
http://dx.doi.org/10.1161/JAHA.120.020646
_version_ 1784610967543349248
author Lee, Yujin
Nemet, Ina
Wang, Zeneng
Lai, Heidi T. M.
de Oliveira Otto, Marcia C.
Lemaitre, Rozenn N.
Fretts, Amanda M.
Sotoodehnia, Nona
Budoff, Matthew
DiDonato, Joseph A.
McKnight, Barbara
Tang, W. H. Wilson
Psaty, Bruce M.
Siscovick, David S.
Hazen, Stanley L.
Mozaffarian, Dariush
author_facet Lee, Yujin
Nemet, Ina
Wang, Zeneng
Lai, Heidi T. M.
de Oliveira Otto, Marcia C.
Lemaitre, Rozenn N.
Fretts, Amanda M.
Sotoodehnia, Nona
Budoff, Matthew
DiDonato, Joseph A.
McKnight, Barbara
Tang, W. H. Wilson
Psaty, Bruce M.
Siscovick, David S.
Hazen, Stanley L.
Mozaffarian, Dariush
author_sort Lee, Yujin
collection PubMed
description BACKGROUND: Trimethylamine N‐oxide (TMAO) is a gut microbiota‐dependent metabolite of dietary choline, L‐carnitine, and phosphatidylcholine‐rich foods. On the basis of experimental studies and patients with prevalent disease, elevated plasma TMAO may increase risk of atherosclerotic cardiovascular disease (ASCVD). TMAO is also renally cleared and may interact with and causally contribute to renal dysfunction. Yet, how serial TMAO levels relate to incident and recurrent ASCVD in community‐based populations and the potential mediating or modifying role of renal function are not established. METHODS AND RESULTS: We investigated associations of serial measures of plasma TMAO, assessed at baseline and 7 years, with incident and recurrent ASCVD in a community‐based cohort of 4131 (incident) and 1449 (recurrent) older US adults. TMAO was measured using stable isotope dilution liquid chromatography–tandem mass spectrometry (laboratory coefficient of variation, <6%). Incident ASCVD (myocardial infarction, fatal coronary heart disease, stroke, sudden cardiac death, or other atherosclerotic death) was centrally adjudicated using medical records. Risk was assessed by multivariable Cox proportional hazards regression, including time‐varying demographics, lifestyle factors, medical history, laboratory measures, and dietary habits. Potential mediating effects and interaction by estimated glomerular filtration rate (eGFR) were assessed. During prospective follow‐up, 1766 incident and 897 recurrent ASCVD events occurred. After multivariable adjustment, higher levels of TMAO were associated with a higher risk of incident ASCVD, with extreme quintile hazard ratio (HR) compared with the lowest quintile=1.21 (95% CI, 1.02–1.42; P‐trend=0.029). This relationship appeared mediated or confounded by eGFR (eGFR‐adjusted HR, 1.07; 95% CI, 0.90–1.27), as well as modified by eGFR (P‐interaction <0.001). High levels of TMAO were associated with higher incidence of ASCVD in the presence of impaired renal function (eGFR <60 mL/min per 1.73 m(2): HR, 1.56 [95% CI, 1.13–2.14]; P‐trend=0.007), but not normal or mildly reduced renal function (eGFR ≥60 mL/min per 1.73 m(2): HR, 1.03 [95% CI, 0.85–1.25]; P‐trend=0.668). Among individuals with prior ASCVD, TMAO associated with higher risk of recurrent ASCVD (HR, 1.25 [95% CI, 1.01–1.56]; P‐trend=0.009), without significant modification by eGFR. CONCLUSIONS: In this large community‐based cohort of older US adults, serial measures of TMAO were associated with higher risk of incident ASCVD, with apparent modification by presence of impaired renal function and with higher risk of recurrent ASCVD.
format Online
Article
Text
id pubmed-8649305
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86493052022-01-14 Longitudinal Plasma Measures of Trimethylamine N‐Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community‐Based Older Adults Lee, Yujin Nemet, Ina Wang, Zeneng Lai, Heidi T. M. de Oliveira Otto, Marcia C. Lemaitre, Rozenn N. Fretts, Amanda M. Sotoodehnia, Nona Budoff, Matthew DiDonato, Joseph A. McKnight, Barbara Tang, W. H. Wilson Psaty, Bruce M. Siscovick, David S. Hazen, Stanley L. Mozaffarian, Dariush J Am Heart Assoc Original Research BACKGROUND: Trimethylamine N‐oxide (TMAO) is a gut microbiota‐dependent metabolite of dietary choline, L‐carnitine, and phosphatidylcholine‐rich foods. On the basis of experimental studies and patients with prevalent disease, elevated plasma TMAO may increase risk of atherosclerotic cardiovascular disease (ASCVD). TMAO is also renally cleared and may interact with and causally contribute to renal dysfunction. Yet, how serial TMAO levels relate to incident and recurrent ASCVD in community‐based populations and the potential mediating or modifying role of renal function are not established. METHODS AND RESULTS: We investigated associations of serial measures of plasma TMAO, assessed at baseline and 7 years, with incident and recurrent ASCVD in a community‐based cohort of 4131 (incident) and 1449 (recurrent) older US adults. TMAO was measured using stable isotope dilution liquid chromatography–tandem mass spectrometry (laboratory coefficient of variation, <6%). Incident ASCVD (myocardial infarction, fatal coronary heart disease, stroke, sudden cardiac death, or other atherosclerotic death) was centrally adjudicated using medical records. Risk was assessed by multivariable Cox proportional hazards regression, including time‐varying demographics, lifestyle factors, medical history, laboratory measures, and dietary habits. Potential mediating effects and interaction by estimated glomerular filtration rate (eGFR) were assessed. During prospective follow‐up, 1766 incident and 897 recurrent ASCVD events occurred. After multivariable adjustment, higher levels of TMAO were associated with a higher risk of incident ASCVD, with extreme quintile hazard ratio (HR) compared with the lowest quintile=1.21 (95% CI, 1.02–1.42; P‐trend=0.029). This relationship appeared mediated or confounded by eGFR (eGFR‐adjusted HR, 1.07; 95% CI, 0.90–1.27), as well as modified by eGFR (P‐interaction <0.001). High levels of TMAO were associated with higher incidence of ASCVD in the presence of impaired renal function (eGFR <60 mL/min per 1.73 m(2): HR, 1.56 [95% CI, 1.13–2.14]; P‐trend=0.007), but not normal or mildly reduced renal function (eGFR ≥60 mL/min per 1.73 m(2): HR, 1.03 [95% CI, 0.85–1.25]; P‐trend=0.668). Among individuals with prior ASCVD, TMAO associated with higher risk of recurrent ASCVD (HR, 1.25 [95% CI, 1.01–1.56]; P‐trend=0.009), without significant modification by eGFR. CONCLUSIONS: In this large community‐based cohort of older US adults, serial measures of TMAO were associated with higher risk of incident ASCVD, with apparent modification by presence of impaired renal function and with higher risk of recurrent ASCVD. John Wiley and Sons Inc. 2021-08-16 /pmc/articles/PMC8649305/ /pubmed/34398665 http://dx.doi.org/10.1161/JAHA.120.020646 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Lee, Yujin
Nemet, Ina
Wang, Zeneng
Lai, Heidi T. M.
de Oliveira Otto, Marcia C.
Lemaitre, Rozenn N.
Fretts, Amanda M.
Sotoodehnia, Nona
Budoff, Matthew
DiDonato, Joseph A.
McKnight, Barbara
Tang, W. H. Wilson
Psaty, Bruce M.
Siscovick, David S.
Hazen, Stanley L.
Mozaffarian, Dariush
Longitudinal Plasma Measures of Trimethylamine N‐Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community‐Based Older Adults
title Longitudinal Plasma Measures of Trimethylamine N‐Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community‐Based Older Adults
title_full Longitudinal Plasma Measures of Trimethylamine N‐Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community‐Based Older Adults
title_fullStr Longitudinal Plasma Measures of Trimethylamine N‐Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community‐Based Older Adults
title_full_unstemmed Longitudinal Plasma Measures of Trimethylamine N‐Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community‐Based Older Adults
title_short Longitudinal Plasma Measures of Trimethylamine N‐Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community‐Based Older Adults
title_sort longitudinal plasma measures of trimethylamine n‐oxide and risk of atherosclerotic cardiovascular disease events in community‐based older adults
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649305/
https://www.ncbi.nlm.nih.gov/pubmed/34398665
http://dx.doi.org/10.1161/JAHA.120.020646
work_keys_str_mv AT leeyujin longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults
AT nemetina longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults
AT wangzeneng longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults
AT laiheiditm longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults
AT deoliveiraottomarciac longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults
AT lemaitrerozennn longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults
AT frettsamandam longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults
AT sotoodehnianona longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults
AT budoffmatthew longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults
AT didonatojosepha longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults
AT mcknightbarbara longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults
AT tangwhwilson longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults
AT psatybrucem longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults
AT siscovickdavids longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults
AT hazenstanleyl longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults
AT mozaffariandariush longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults